Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

In phase II and phase III, there are several compounds targeting tau, especially monoclonal antibodies (such as E2814, ...

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

Begin your TipRanks Premium journey today. Percheron Therapeutics (PERCF) Company Description: Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals.

Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

This innovative approach, in partnership with the Cancer Science Institute of Singapore (CSI Singapore), A*STAR, National ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.